Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25736995 | 0.85 | TLR8 (0.40) | TLR8TLR7NOS2NOS3NOS1 | |
| SCHEMBL22024946 | 0.81 | TLR8 (0.33) | TLR8TLR7P2RY1NAPRT | |
| SCHEMBL25736998 | 0.80 | NOS2 (0.45) | NOS2NOS3NOS1HPGDLTA4H | |
| SCHEMBL21191715 | 0.76 | SMN1; SMN2 (0.41) | TLR8TLR7HPGDKDM4EALDH1A1 | |
| SCHEMBL22624032 | 0.75 | P2RY1 (0.39) | TLR8TLR7HPGDP2RY1KDM4E | |
| SCHEMBL21191599 | 0.75 | TLR8 (0.35) | TLR8TLR7P2RY1NAPRTKDM4E | |
| SCHEMBL21191754 | 0.74 | TLR8 (0.36) | TLR8TLR7P2RY1KDM4ENPC1 | |
| SCHEMBL22024146 | 0.73 | NAPRT (0.34) | TLR8HPGDNAPRTKDM4EALDH1A1 | |
| SCHEMBL21191591 | 0.73 | TLR8 (0.36) | TLR8TLR7P2RY1NAPRTKDM4E | |
| SCHEMBL22624021 | 0.73 | TLR8 (0.34) | TLR8TLR7NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | TLR8 4180/4885TLR7 4597/4885NOS2 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.